A double-blind, placebo-controlled phase Ila study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy

Eitemau Tebyg

• A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy
  gan: Senti, G, et al.
  Cyhoeddwyd: (2007)
• Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
  gan: Klimek, L, et al.
  Cyhoeddwyd: (2011)
• Cytokine production by peripheral blood cells following therapy with a combined vaccine of allergen and QbG10
  gan: Manolova, V, et al.
  Cyhoeddwyd: (2008)
• Dust mite allergy - New treatment options
  gan: Haug, S, et al.
  Cyhoeddwyd: (2007)
• The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
  gan: Beeh, K, et al.
  Cyhoeddwyd: (2013)